News Quantified

GMAB – genmab a/s - american depositary shares (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Major Shareholder Announcement

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026

Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer

Genmab: Multiple Binaries Could Alter The Thesis [Seeking Alpha]

Major Shareholder Announcement

Top News Gainers

8/14 Genmab Announces Financial Results for the First Half of 2019 and Updates 2019 Financial Guidance 6.0%

10/15 Swiss stocks - Factors to watch on October 15 [Reuters] 3.6%

2/19 Genmab A/S (GMAB) Q4 2019 Earnings Call Transcript [The Motley Fool] 3.1%

5/1 Genmab A/S (NASDAQ: GMAB) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 2.8%

1/22 Genmab Announces 2019 Net Sales Figures for DARZALEX® (daratumumab) and Achievement of USD 150 Million Sales Milestone in DARZALEX Collaboration with Janssen 2.4%

2/19 Genmab Publishes 2019 Annual Report 2.0%

10/12 Genmab: A Rising Star In Biotech [Seeking Alpha] 1.5%

12/3 Genmab A/S (NASDAQ: GMAB) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 1.4%

11/6 Genmab Announces Financial Results for the First Nine Months of 2019 1.3%

10/16 Genmab A/S (NASDAQ: GMAB) had its price target raised by analysts at HC Wainwright from $24.00 to $25.00. They now have a "buy" rating on the stock. 1.2%

Top News Decliners

3/10 Genmab Announces Appointment of Anthony Mancini to Newly Created Position of Chief Operating Officer -6.4%

12/11 Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock. -3.3%

2/28 Genmab A/S (NASDAQ: GMAB) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -2.6%

2/12 Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock. -2.0%

4/6 Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $27.00 price target on the stock. -2.0%

9/13 Detailed Results from the Phase III ASCLEPIOS I & II Studies of Ofatumumab in Patients with Relapsing Multiple Sclerosis Presented at ECTRIMS -1.4%

9/30 Genmab A/S (NASDAQ: GMAB) was given a new $24.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. -1.4%

9/9 Genmab and Tempus Enter into Strategic Collaboration Agreement -1.2%

3/5 Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $29.00 price target on the stock. -1.2%

8/12 Genmab A/S (NASDAQ: GMAB) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock. -0.9%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day